Related Experiment Video
Updated: Jan 29, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Omalizumab and unmet needs in severe asthma and allergic comorbidities in Japanese children
Sankei Nishima1, Masanari Kozawa2, Ki Lee Milligan2
1National Hospital Organization, Fukuoka National Hospital, Fukuoka, Japan.
Insights
Omalizumab, an anti-IgE therapy, is approved for childhood asthma in Japan. This review covers Japanese clinical insights, allergic comorbidities, and future opportunities for this important pediatric asthma treatment.
Area of Science:
- Pediatric Allergy and Immunology
- Respiratory Medicine
Background:
- Childhood asthma is a common allergic disease.
- Omalizumab (anti-IgE therapy) was approved for pediatric asthma in Japan in 2017.
- Allergic diseases share common pathways and comorbidities.
Purpose of the Study:
- To review Japanese clinical perspectives on pediatric allergic asthma.
- To consider allergic comorbidities in pediatric asthma management.
- To discuss ongoing omalizumab clinical trials and future opportunities.
Main Methods:
- Literature review of Japanese clinical studies and guidelines.
- Analysis of omalizumab's role in pediatric allergic asthma.
- Examination of clinical trial data and future research directions.
Main Results:
- Omalizumab is an established therapy for pediatric asthma in Japan.
- Management of allergic comorbidities is crucial for effective asthma control.
- Ongoing trials are expanding the understanding of omalizumab's efficacy and safety.
Conclusions:
- Omalizumab offers a valuable treatment option for pediatric allergic asthma in Japan.
- A comprehensive approach addressing comorbidities is essential.
- Further research will refine omalizumab's application in pediatric allergy.
Abstract:
Childhood asthma is one condition within a family of allergic diseases, which includes allergic rhinitis, atopic dermatitis, and food allergy, among others. Omalizumab is an anti-IgE antibody therapy that was approved in Japan for children with asthma and added to the Japanese pediatric asthma guidelines in 2017. This review highlights the Japanese clinical perspectives in pediatric allergic asthma, and consideration for allergic comorbidities, and reflects on omalizumab clinical trials in progress to present comprehensive future opportunities.
More Related Videos
09:37Detection of Polyfunctional T Cells in Children Vaccinated with Japanese Encephalitis Vaccine via the Flow Cytometry Technique
Published on: September 23, 2022
05:32Comparing Eye-tracking Data of Children with High-functioning ASD, Comorbid ADHD, and of a Control Watching Social Videos
Published on: December 7, 2018
Related Concept Videos
Allergic Reactions
Asthma-I: Introduction
Allergic Drug Reactions
Asthma-III: Symptoms and Complications
Classification of Asthma
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.